Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033

23 Jun 2025

Share :

Table of Content

1. Knee Osteoarthritis (OA) Injectable Treatments Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Outlook 4. Regional Insights 5. Knee Osteoarthritis (OA) Injectable Treatments Market Coverage 6. Knee Osteoarthritis (OA) Injectable Treatments Market Key Players

Knee Osteoarthritis (OA) Injectable Treatments Market Revenue and Trends 2025 to 2033

The global knee osteoarthritis (OA) injectable treatments market revenue surpass USD 3.46 billion in 2025 and is predicted to attain around USD 5.94 billion by 2033, growing at a CAGR of 7%. The global knee osteoarthritis (OA) injectable treatments market is witnessing significant momentum, propelled by rising awareness of non-surgical therapies and the need for long-term joint health management.

Market Overview

The knee osteoarthritis injectable treatments market is undergoing a transformation, fueled by increased demand for non-surgical, minimally invasive interventions. These treatments, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies, offer patients a path to pain relief and functional restoration without surgical downtime. Viscosupplements continue to dominate early-stage OA treatment due to their accessibility and safety profile, while biologics are reshaping therapeutic goals from symptom suppression to joint regeneration.

Biologic injectables, particularly PRP and stem cell formulations, are increasingly being integrated into orthopedic and sports medicine practices as alternatives to surgical interventions. The trend is especially prominent in younger patient populations and active adults who seek to preserve joint function without compromising lifestyle. Furthermore, as more clinical evidence supports their efficacy, the demand for biologic-based injectable treatments is anticipated to grow rapidly.

Segment Outlook

• By product type, the viscosupplements segment held the largest market share in 2024, owing to their wide use in treating mild to moderate OA. On the other hand, stem cell therapy injections are projected to grow at the fastest CAGR over the forecast period. 
• By mechanism of action, the lubrication segment dominated the market in 2024 due to the widespread adoption of viscosupplementation techniques. Its use is prevalent among aging populations who are less suited for surgery and benefit from a non-systemic, localized solution. It produces viscous synovial fluid. Additionally, regenerative therapies such as PRP, stem cells, and autologous protein solutions are poised to register the highest growth.
• By disease severity, the mild knee OA segment led the market in 2024, as most injectable treatments are administered during the early stages of the disease to delay progression and manage symptoms conservatively.
• By age group, the >60 years segment accounted for the largest share in 2024. Viscosupplements and corticosteroids remain the most used treatments in this demographic due to their affordability, tolerability, and rapid pain relief.
• By duration/dosing frequency, the single-dose therapy segment dominated the market in 2024, as it offers a convenient and cost-effective treatment solution with fewer clinical visits.
• By end-user, the hospitals segment led the market in 2024 due to their comprehensive capabilities in diagnosis, imaging, and complex treatment administration.

Regional Insights

North America held the largest share of the knee OA injectable treatments market in 2024. This is mainly due to the existence of a strong healthcare system, an aging demography, and the increased prevalence of osteoarthritis. The U.S. is a leader in the proportion of clinical research, regulatory approvals, and supply of advanced injectable formulations, contributing to regional market growth.

Asia Pacific is poised to register the highest growth during the forecast period. The increasing OA prevalence, an aging population, and increased awareness regarding regenerative therapies are driving the growth of the market in the region. Regulatory approvals and insurance coverage for innovative biologics in countries such as China and Japan are also supporting market expansion. Furthermore, the increasing outpatient services and the rising healthcare expenditures by the middle class are expected to fuel the market in the coming years.

Knee Osteoarthritis (OA) Injectable Treatments Market Coverage

Recent Development

• In March 2025, NeuPath Health Inc. announced that it has performed the first-ever injection of Arthrosamid in North America at its clinic located in Mississauga, Ontario. This injection provides up to four years of pain relief for individuals suffering from knee osteoarthritis.
  (Source: https://www.businesswire.com)

Knee Osteoarthritis (OA) Injectable Treatments Market Key Players

• Alcon, Inc.
• Allergan plc
• Anika Therapeutics, Inc.
• Arthrex, Inc.
• Bioventus, Inc.
• Ferring Pharmaceuticals Inc.
• Fidia Farmaceutici S.p.A.
• Flexion Therapeutics, Inc.
• Galderma S.A.
• Hyaltech Ltd.
• Landec Corporation (LifeCore Biomedical, Inc.)
• Meiji Seika Pharma Ltd.
• Merz Pharmaceuticals GmbH (Merz Aesthetics, Inc.)
• OrthogenRx, Inc.
• Roche Holding AG (F. Hoffmann-La Roche AG)
• Royal Biologics
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6270

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344